ZA931585B - Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use. - Google Patents

Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use.

Info

Publication number
ZA931585B
ZA931585B ZA931585A ZA931585A ZA931585B ZA 931585 B ZA931585 B ZA 931585B ZA 931585 A ZA931585 A ZA 931585A ZA 931585 A ZA931585 A ZA 931585A ZA 931585 B ZA931585 B ZA 931585B
Authority
ZA
South Africa
Prior art keywords
biphenylsulfonylurethane
biphenylsulfonylurea
preparation
side chain
imidazole derivatives
Prior art date
Application number
ZA931585A
Other languages
English (en)
Inventor
Holger Heitsch
Adalbert Wagner
Reinhard Becker
Rainer Henning
Hermann Gerhards
Bernward Schoelkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA931585B publication Critical patent/ZA931585B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA931585A 1992-03-07 1993-03-05 Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use. ZA931585B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07

Publications (1)

Publication Number Publication Date
ZA931585B true ZA931585B (en) 1993-09-27

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA931585A ZA931585B (en) 1992-03-07 1993-03-05 Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use.

Country Status (25)

Country Link
US (1) US5604251A (fr)
EP (1) EP0560177B1 (fr)
JP (1) JP3542813B2 (fr)
KR (1) KR930019637A (fr)
CN (1) CN1036341C (fr)
AT (1) ATE230732T1 (fr)
AU (1) AU663565B2 (fr)
BR (1) BR9300761A (fr)
CA (1) CA2091135A1 (fr)
CZ (1) CZ281983B6 (fr)
DE (1) DE59310323D1 (fr)
DK (1) DK0560177T3 (fr)
ES (1) ES2187501T3 (fr)
FI (1) FI930970A7 (fr)
HU (1) HUT64041A (fr)
IL (1) IL104971A0 (fr)
MA (1) MA22814A1 (fr)
NO (1) NO303632B1 (fr)
NZ (1) NZ247059A (fr)
PH (1) PH31466A (fr)
PL (1) PL173023B1 (fr)
RU (1) RU2116300C1 (fr)
SK (1) SK279109B6 (fr)
TW (1) TW215434B (fr)
ZA (1) ZA931585B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
PL328571A1 (en) 1996-02-20 1999-02-01 Bristol Myers Squibb Co Methods of obtaining biphenylisoxazol sulphonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP4269015B2 (ja) * 1996-12-13 2009-05-27 オステオスクリーン アイピー， エルエルシー 骨の成長を刺激する組成物および方法
EP0855392A3 (fr) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Hétérocycles à cinq chaínons contenant des substituants biphénylylsulphoniques, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
HK1039778A1 (zh) 1999-03-19 2002-05-10 Bristol-Myers Squibb Company 制造联苯异恶唑基磺胺的方法
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004002226A1 (fr) * 2002-06-28 2004-01-08 Baylor College Of Medicine Modulateurs de cdk9 utilises comme cible therapeutique dans l'hypertrophie cardiaque
MXPA05012619A (es) * 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
WO2006074147A2 (fr) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Composes et utilisation therapeutique associee
WO2005003100A2 (fr) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Composes et leur utilisation therapeutique
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004285961A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
DE602004015321D1 (de) * 2003-11-03 2008-09-04 Myogen Inc 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
JP2007514665A (ja) * 2003-12-12 2007-06-07 ミオゲン インコーポレイティッド エノキシモン製剤ならびに心肥大および心不全の治療へのそれらの使用方法
CA2560538A1 (fr) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxyde et son utilisation dans le traitement de maladies induites par pde-iii
WO2005092332A1 (fr) * 2004-03-22 2005-10-06 Myogen, Inc. Sulfoxyde de (s)-enoximone et son utilisation dans le traitement de maladies mediees par pde-iii
CA2572179A1 (fr) * 2004-06-23 2006-01-19 Myogen, Inc. Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2007014033A2 (fr) * 2005-07-22 2007-02-01 The Regents Of The University Of Colorado, A Body Corporate Inhibition de la kinase erk 1/2 ('extracellular signal-regulated kinase') servant a traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
CA2634437A1 (fr) * 2005-12-20 2007-07-05 Gilead Colorado, Inc. Composes de 4,7-dihydrothieno¬2,3-b|pyridine et compositions pharmaceutiques
BRPI0714794A2 (pt) 2006-08-01 2013-05-21 Univ Texas identificaÇço de um micro-rna que ativa a expressço da cadeia pesada de beta-miosina
ES2621161T3 (es) 2007-07-31 2017-07-03 The Board Of Regents Of The University Of Texas System Familia de micro-ARN que modula la fibrosis y usos de la misma
JP5653899B2 (ja) 2008-03-17 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 神経筋シナプスの維持および再生に関与するマイクロｒｎａの同定
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
SU1518949A1 (ru) * 1987-04-09 1995-04-30 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получения инъекционного раствора 5-этокси-2-этилтиобензимидазола
CA1338238C (fr) * 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (fr) * 1991-01-04 1992-07-05 Adalbert Wagner Procede de preparation et utilisation de derives d'azole
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
JPH06510762A (ja) * 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンジオテンシン２受容体遮断イミダゾリノン誘導体
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体

Also Published As

Publication number Publication date
PL297955A1 (en) 1993-09-20
RU2116300C1 (ru) 1998-07-27
MA22814A1 (fr) 1993-10-01
JP3542813B2 (ja) 2004-07-14
ES2187501T3 (es) 2003-06-16
DK0560177T3 (da) 2003-04-14
PL173023B1 (pl) 1998-01-30
CA2091135A1 (fr) 1993-09-08
AU663565B2 (en) 1995-10-12
CN1036341C (zh) 1997-11-05
FI930970A7 (fi) 1993-09-08
FI930970A0 (fi) 1993-03-04
PH31466A (en) 1998-11-03
CZ281983B6 (cs) 1997-04-16
EP0560177B1 (fr) 2003-01-08
DE59310323D1 (de) 2003-02-13
CN1076192A (zh) 1993-09-15
HUT64041A (en) 1993-11-29
SK381192A3 (en) 1998-06-03
AU3401193A (en) 1993-09-09
JPH069572A (ja) 1994-01-18
TW215434B (fr) 1993-11-01
HU9300618D0 (en) 1993-05-28
IL104971A0 (en) 1993-07-08
ATE230732T1 (de) 2003-01-15
BR9300761A (pt) 1993-09-14
NZ247059A (en) 1995-03-28
NO930817D0 (no) 1993-03-05
CZ381192A3 (en) 1993-12-15
US5604251A (en) 1997-02-18
EP0560177A1 (fr) 1993-09-15
NO303632B1 (no) 1998-08-10
SK279109B6 (sk) 1998-06-03
NO930817L (no) 1993-09-08
KR930019637A (ko) 1993-10-18

Similar Documents

Publication Publication Date Title
IL104971A0 (en) Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain,process for their preparation and their use
HUT62892A (en) Process for producing iso-and heterocyclic compounds furnished with imidazole ring and pharmaceutical compositions comprising same as active ingredient
RU93004577A (ru) Производные имидазола с боковой цепью бифенилсульфонилмочевины
PH30954A (en) Azole derivatives, process for their preparation and their use.
CA2064634A1 (fr) Derives de 9-desoxo-8a-aza-8a-homoerythromycine a modifies en positions 4"- et 8a
AU4755393A (en) Azaquinoxalines, processes for their preparation and their use
IL114894A0 (en) Endothelin antagonists
CA2371012A1 (fr) Imidazoles 4-(1h-pyrol-1-yl)
AU4149293A (en) 4-iminoquinolines, processes for their preparation, and their use
HU9503025D0 (en) Alkyl-5-methyl-sulphonyl-benzoyl-guanidine derivatives
ZA929175B (en) 5,6-dihydro-dibenz(b,e)azepine-6,11-dione-11-oximes.
IT1255093B (it) Derivati imidazolidinonici come agenti nootropici